Biobehavioral Correlates of Acute Phobic Fear

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-02-04

Study Completion Date

2019-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study seeks to measure the time course of circulating proinflammatory markers (interleukin-1 beta \[IL-1β\], interleukin-6 \[IL-6\], tumor necrosis factor alpha \[TNF-α\], and C-reactive protein \[CRP\]) and salivary alpha amylase (sAA) following laboratory fear arousal. Further, this study seeks to implement neurocognitive, physiological, and self-report measures to explore the role of threat sensitivity as a predictor of this response. The broad research question seeks to better understand the relationship between neurocognitive fear and subsequent stress responding elicited by both the immune system (i.e., proinflammatory markers) and autonomic nervous system (i.e., sAA). In light of these aims, the primary outcomes of the current study are the proinflammatory markers (IL-1β, IL-6, TNF-α, CRP), while secondary outcomes consist of sAA, neurocognitive measures (i.e., dot-probe task), physiological correlates (i.e., heart rate, galvanic skin response), and self-report measures.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intracranial Neurophysiological Signatures of Fear and Anxiety in Humans

NCT05120635

Fear GAD Emotional Memory +1 more

RECRUITING NA

Cannabinoid Augmentation of Fear Response in Humans

NCT01665573

Fear Conditioning

COMPLETED EARLY_PHASE1

Neurobiology of Generalized Fear-Conditioning & Avoidance in Anxiety Disorders

NCT03033056

Anxiety Disorders

COMPLETED

Threat-Avoidance Learning in Anxiety Patients

NCT02336802

Panic Disorder Phobic Disorders Stress Disorders, Traumatic

UNKNOWN

Effect of Cognitive-behavior Therapy on Fear Responses to Body Symptoms in Patients With Panic Disorder

NCT04568109

Panic Disorder With Agoraphobia Panic Disorder Without Agoraphobia

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Phobia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Phobic

Adults aged 18-40 exhibiting high levels of self-reported phobic symptoms to spiders

Fear tasks

Intervention Type BEHAVIORAL

All participants will be exposed to 5 fear tasks involving spiders, with increasing fear intensity.

Nonphobic

Adults aged 18-40 exhibiting low levels of self-reported phobic symptoms to spiders

Fear tasks

Intervention Type BEHAVIORAL

All participants will be exposed to 5 fear tasks involving spiders, with increasing fear intensity.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fear tasks

All participants will be exposed to 5 fear tasks involving spiders, with increasing fear intensity.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 - 40 years old
* Phobic or nonphobic fear of spiders.
* Willing to proceed through 5-stimulus fear hierarchy or maintain 7 or higher subjective units of distress through fear task (see Procedures section).

Exclusion Criteria

* Lifetime history of serious mental illness
* Lifetime history of intellectual or developmental delays
* Lifetime history of chronic physical or medical illness including blood clotting disorders
* Lifetime history of allergies to latex
* Lifetime history of hormonal replacement therapy
* Lifetime history of blindness
* Lifetime history of blood/injection phobia or aversion to needles/injection (based on IPS-Anx and MQ)
* Substance abuse in the past 2 years
* Cigarette/tobacco use in the past 2 years
* Major depression within the past 12 months
* Traumatic stress within the past 12 months
* Pregnancy within the past 12 months
* Anesthesia within the past 3 months
* Night shift work within the past month
* Use of medication within the past month (except for oral contraception)
* Acute illness or infection within the past month
* Average sleep outside of 6 - 10 hours per night within the past month
* Average intake of 4 or more alcoholic beverages per week
* Average intake of 6 or more cups caffeine per day
* Use of marijuana within the week before the laboratory session
* Use of alcohol within the week before the laboratory session
* Body mass index outside of 18.5 - 24.9 range

Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes